A Review of Complement Activation in SLE
- PMID: 33569681
- PMCID: PMC7875837
- DOI: 10.1007/s11926-021-00984-1
A Review of Complement Activation in SLE
Abstract
Purpose of review: Complement activation is a key event in the pathogenesis of tissue inflammation and injury in systemic lupus erythematosus (SLE). This review is aimed at comparing the usefulness of measurement of complement proteins in serum/plasma (C3, C4) to complement activation (split) products in plasma and on circulating blood cells for SLE diagnosis, disease monitoring, and prognosis.
Recent findings: Complement split products, C3dg, iC3b, and C4d, are elevated in SLE, and C3dg/C3 and iC3b/C3 ratios correlate with active SLE. C4d also is higher in patients with lupus nephritis. An elevated level of the alternative pathway split product, Bb, in early lupus pregnancy is a predictor of adverse outcomes in SLE patients with antiphospholipid antibodies. Elevated levels of cell-bound complement activation products (CB-CAPs), namely, B cell-bound C4d (BC4d) and erythrocyte-bound C4d (EC4d), within a multiparameter assay panel, may predict transition to SLE more than other lupus biomarkers. EC4d better correlates with lupus disease activity than low plasma complement levels. Elevated platelet-bound C4d (PC4d) correlates with thrombosis in SLE. Both EC4d and PC4d are increased in primary and secondary anti-phospholipid syndrome, and anti-beta2glycoproteinI antibodies may directly activate the complement system. Abnormal levels of plasma complement split products and CB-CAPs support complement activation as an important pathogenetic mechanism in SLE and the antiphospholipid syndromes. These tests show promise for the diagnosis of SLE and monitoring of disease activity.
Keywords: Complement; Complement activation measurement; Disease activity; Lupus nephritis; Systemic lupus erythematosus.
Conflict of interest statement
AW is a research consultant to Exagen Inc. He has received > $10,000 stock options. RVA and DJA are employees of Exagen Inc.
Figures
Similar articles
-
Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome.Front Immunol. 2019 Apr 12;10:773. doi: 10.3389/fimmu.2019.00773. eCollection 2019. Front Immunol. 2019. PMID: 31031764 Free PMC article.
-
Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.Lupus. 2018 Dec;27(14):2262-2268. doi: 10.1177/0961203318809181. Epub 2018 Oct 30. Lupus. 2018. PMID: 30376789
-
Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.Arthritis Rheum. 1996 Jul;39(7):1178-88. doi: 10.1002/art.1780390716. Arthritis Rheum. 1996. PMID: 8670328
-
Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis.Lupus. 2024 Feb;33(2):111-120. doi: 10.1177/09612033231226351. Epub 2024 Jan 16. Lupus. 2024. PMID: 38227433 Review.
-
Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy.Am J Reprod Immunol. 1992 Oct-Dec;28(3-4):183-7. doi: 10.1111/j.1600-0897.1992.tb00787.x. Am J Reprod Immunol. 1992. PMID: 1285875 Review.
Cited by
-
Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials.BMC Med. 2024 Mar 13;22(1):110. doi: 10.1186/s12916-024-03303-4. BMC Med. 2024. PMID: 38475833 Free PMC article.
-
Diagnostic potential of NRG1 in benign nerve sheath tumors and its influence on the PI3K-Akt signaling and tumor immunity.Diagn Pathol. 2024 Feb 8;19(1):28. doi: 10.1186/s13000-024-01438-9. Diagn Pathol. 2024. PMID: 38331905 Free PMC article.
-
Causal associations between circulating inflammatory cytokines and blinding eye diseases: a bidirectional Mendelian randomization analysis.Front Aging Neurosci. 2024 Jan 23;16:1324651. doi: 10.3389/fnagi.2024.1324651. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38327497 Free PMC article.
-
Acute Encephalopathy Workup for a Patient With a History of Lupus Cerebritis and Unremarkable Inflammatory Markers: A Case Report.Cureus. 2024 Jan 5;16(1):e51699. doi: 10.7759/cureus.51699. eCollection 2024 Jan. Cureus. 2024. PMID: 38313902 Free PMC article.
-
JAK/STAT Signaling Predominates in Human and Murine Fungal Post-infectious Inflammatory Response Syndrome.medRxiv [Preprint]. 2024 Jan 21:2024.01.18.24301483. doi: 10.1101/2024.01.18.24301483. medRxiv. 2024. PMID: 38293201 Free PMC article. Preprint.
References
-
- Vaughan JH, Bayles TB, Favour CB. The response of serum gamma globulin level and complement titer to adrenocorticotropic hormone (ACTH) therapy in lupus erythematosus. J Lab Clin Med. 1951;37:698–702. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
